Artificial Intelligence healthcare developer Viz.ai has raised $21 million in a Series A funding round joined by GV, formerly known as Google Ventures.
The round was led by Kleiner Perkins, the San Francisco-based company said. In connection with the funding round, Kleiner Perkins general partner Mamoon Hamid will join the company’s board of directors.
“We were attracted not only to the technology behind Viz.ai and its impact on patient outcomes, but also its adoption model. Many new health-tech solutions struggle to gain traction because they are an outside-in sale to medical teams, requiring changes to procedures and workflows. In contrast, physicians and their teams are driving adoption of the Viz.ai platform because it is not disruptive to emergency room procedures and fits naturally into existing systems,” Hamid said in a press release.
Funds from the round will support market expansion and to extend their product portfolio beyond stroke care, Viz.ai said.
“In stroke every minute matters. Our goal is to fundamentally change healthcare, making it proactive rather than reactive. By integrating Viz, we believe healthcare systems can increase access to proven life saving therapy and reduce the time to treatment across their referral network. AI-assisted triage has the potential to save lives and reduce disability. We are delighted to partner with top tier investors at Kleiner Perkins and GV,” founder Dr. Chris Mansi said in a prepared statement.
In April, Viz.ai said it won FDA 510(k) clearance for its Viz CTP computed tomography perfusion image processing and analysis software.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.